Modulating Bet Bromodomain Inhibitor Zen-3694 And Enzalutamide Combination Dosing In A Metastatic Prostate Cancer Patient Using Curate.Ai, An Artificial Intelligence Platform

Combination chemotherapy is a cornerstone of cancer treatment. Optimizing its effectiveness requires dose- and time-dependent regulation of drug synergy. In this report, CURATE.AI, an artificial intelligence platform, is used to prospectively guide the dosing of a bromodomain inhibitor (ZEN-3694) and enzalutamide administered in combination to a patient with metastatic castration-resistant prostate cancer to reduce serum prostate-specific antigen (PSA) levels. CURATE.AI successfully identifies substantial ZEN-3694 and enzalutamide dose adjustments, increasing both treatment efficacy and tolerance. CURATE.AI analysis also confirms that the patient's durable response is mediated by ZEN-3694 inclusion in the regimen. Due to CURATE.AI-enhanced efficacy and safety, the patient was able to continue with the combination regimen, resulting in a durable response and no disease progression based on CURATE.AI-sustained control over PSA levels and reduced lesion size.